A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

Provided is a liquid composition for ophthalmic products. The liquid composition includes a buffer solution and a zinc salt dissolved in the buffer solution. The zinc salt has a weight percentage concentration of 1×10.sup.−5% to 3% in the liquid composition. The liquid composition may also include a first vitamin dissolved in the buffer solution. The first vitamin has a weight percentage concentration of 1×10.sup.−5% to 1% in the liquid composition. The first vitamin includes vitamin B2, a vitamin B2 derivative, or a combination thereof.

Provided is a liquid composition for ophthalmic products. The liquid composition includes a buffer solution and a zinc salt dissolved in the buffer solution. The zinc salt has a weight percentage concentration of 1×10.sup.−5% to 3% in the liquid composition. The liquid composition may also include a first vitamin dissolved in the buffer solution. The first vitamin has a weight percentage concentration of 1×10.sup.−5% to 1% in the liquid composition. The first vitamin includes vitamin B2, a vitamin B2 derivative, or a combination thereof.

The present invention relates to novel peptides and a pharmaceutical compositions comprising the same. The peptide compounds and compositions disclosed herein are useful as therapeutic agents for treating eye diseases. When administered to the eyes, the peptide compounds and compositions disclosed herein increase the amount of tear secretion and promotes recovery of a damaged cornea.

The present invention relates to novel peptides and a pharmaceutical compositions comprising the same. The peptide compounds and compositions disclosed herein are useful as therapeutic agents for treating eye diseases. When administered to the eyes, the peptide compounds and compositions disclosed herein increase the amount of tear secretion and promotes recovery of a damaged cornea.

The present invention relates to methods and kits for treating cardiovascular disease.

A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.

The present disclosure provides methods for treating, preventing, or inhibiting diseases in patients having one or more CFI mutations.

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.